World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 18 March 2013
Main ID:  EUCTR2008-001405-41-DE
Date of registration: 28/08/2008
Prospective Registration: Yes
Primary sponsor: GMIHO mbH
Public title: A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX
Scientific title: A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX
Date of first enrolment: 24/10/2008
Target sample size:
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001405-41
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: Placebo: Other:  
Phase: 
Countries of recruitment
Germany
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
- Untreated patients with systemic AL amyloidosis
- Age between 18 and 74 years
- Not eligible for or refused high-dose chemotherapy
- NYHA stage < IV
- Measurable plasma cell disorder

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
- Multiple myeloma stage II and III
- Not able to visit the Amyloidosis Clinic in Heidelberg once per months
- Pregnant or breast feeding females
- Not able to give informed consent



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
AL amyloidosis
Intervention(s)

Trade Name: Revlimid
Pharmaceutical Form: Capsule*
Other descriptive name: Lenalidomide
Concentration unit: IU/mg international unit(s)/milligram
Concentration number: 5 mg-

Trade Name: Alkeran
Product Code: L01AA03
Pharmaceutical Form: Film-coated tablet
Other descriptive name: melphalan
Concentration unit: IU/mg international unit(s)/milligram
Concentration number: 2 mg-

Trade Name: Fortecortin
Pharmaceutical Form: Tablet
Other descriptive name: dexamethasone
Concentration unit: IU/mg international unit(s)/milligram
Concentration number: 4 mg-

Primary Outcome(s)
Main Objective: Evaluate rate of complete remission
Primary end point(s): CR rate after 6 cycles of L-M-Dex
Secondary Objective: toxicity, rate of haematological response and organ response, correlation of cytogenetic aberrations and GEP results with haematological response, retrospective comparison with historical controls treated with M-Dex
Secondary Outcome(s)
Secondary ID(s)
GMIHO-005/2007 (191063)
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history